医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Lorien Health Systems to Roll Out Simavita’s SIM™ across Its US Facilities

2014年09月16日 PM10:00
このエントリーをはてなブックマークに追加


 

SYDNEY

Simavita Limited (ASX:SVA)(TSX-V:SV)(“Simavita” or the “Company”) is pleased to announce that the Company’s exclusive US distribution partner, Medline Industries, Inc. (“Medline”), has advised that it has executed an agreement under which it will roll out Simavita’s SIMTM incontinence assessment and management solution across all of the Skilled Nursing facilities operated by US aged care provider, Lorien Health Systems (“Lorien”.)

Lorien, a leader in the provision of aged care services in the US, has in excess of 1,400 beds under management in its nine Skilled Nursing facilities (roughly 800 beds) and five Assisted Living facilities (roughly 600 beds) in the State of Maryland. Under the agreement, it is expected that, commencing from the end of September 2014, the SIM™ system will be rolled out across all of Lorien’s Skilled Nursing facilities, replacing the numerous manual continence assessments which are currently being undertaken.

It is anticipated that under the agreement, Lorien, an existing Medline customer, will conduct approximately 700 SIM™ assessments across its nine Skilled Nursing facilities and that the value of this agreement to Medline over the one year life of the contract will be in the order of US$250,000.

“Simavita is pleased to see sales momentum building around our Smart Incontinence Management (SIM™) system in the US, and Lorien’s belief in evidence-based practices makes SIMTM an ideal fit for their business” said Simavita CEO Ms. Philippa Lewis. “We expect the SIM™ system will deliver a range of important economic benefits to Lorien’s facilities as well as health benefits to their residents and we are excited about working together with Medline to bring them to fruition”, she said.

For further information, please visit our website (www.simavita.com) or contact the persons named below.

CONTACT

Company
Simavita Limited
Philippa Lewis, Chief
Executive Officer
T: +61-2-8405-6381
Tom Howitt, CFO and
Company Secretary
T: +61-2-8405-6391
or
Media and
Investor Relations

Buchan Consulting
Jane Lowe
E: jlowe@buchanwe.com.au
T:
+61-2-9237-2800

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表
  • Intercell USA Changes Name to Valneva USA, Inc. and Expands Commercial Presence
  • ADC Therapeutics präsentiert Zwischenergebnisse aus Phase-I-Studie zu neuartigem Antikörper-Wirkstoff-Konjugat ADCT-402
  • Bertin与Zymo Research宣布达成新的合作